Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

Axumin, fluciclovine F-18 injection, first injection, Northside Hospital Atlanta
News | Radiopharmaceuticals and Tracers | September 07, 2016

September 7, 2016 — Blue Earth Diagnostics announced that the first post-U.S. Food and Drug Administration (FDA)...

News | Radiopharmaceuticals and Tracers | September 06, 2016

September 6, 2016 — Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with...

ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016

September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...

Lantheus, Xenon 133 gas, radiopharmaceuticals, IRE, Institute for Radioelements Belgium
News | Radiopharmaceuticals and Tracers | July 12, 2016

July 12, 2016 — Lantheus Holdings Inc., the parent company of Lantheus Medical Imaging Inc. (LMI), announced the...

Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent
News | Radiopharmaceuticals and Tracers | July 07, 2016

July 7, 2016 — Cell>Point announced in mid-June it has entered into an...

Navidea, Lymphoseek injection, breast cancer detction, scintigraphy, SNMMI 2016
News | Radiopharmaceuticals and Tracers | July 06, 2016

July 6, 2016 — Navidea Biopharmaceuticals Inc. announced results from three investigator-initiated studies of the...

blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016

June 23, 2016 — Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and...

PET, neuroinflammation, multiple sclerosis, MS, Adam Rosenberg, SNMMI 2016

A. Increased F-18 TZ3504 uptake was observed in the inflamed lumbar spinal cord of EAE-treated animals in the rat model of MS compared to sham control rats. Representative sagittal, coronal and transverse views of the thoracic and lumbar spine are shown. B. The time activity curve of F-18 TZ3504 uptake in the lumbar spinal cord was significantly higher for the first 30 minutes in EAE-treated rats. C. F-18 TZ3504 was able to cross the blood brain barrier and showed homogeneous distribution in the brain of a healthy nonhuman primate. Image Credit:  Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Mo.

News | PET Imaging | June 23, 2016

June 23, 2016 — The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many...

neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016

June 23, 2016 — Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering...

pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016

June 20, 2016 — An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting...

SNMMI, Image of the Year 2016, PET, Alzheimer's disease, amyloid plaques

Topographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer’s disease

Right lateral surface of projected z-score images, reflecting deviation from healthy controls

Yellow/red: higher uptake, blue: lower uptake as compared to controls

Image courtesy of G. Bischof, J. Hammes, T. van Eimeren, A. Drzezga, Multimodal Neuroimaging Group, Dept. of Nuclear Medicine, University of Cologne; B. Neumaier, Institute of Radiochemistry and Experimental Molecular Imaging University of Cologne; J. Dronse, O. Onur, J. Kukolja, G. Fink, F. Jessen, Center for Memory Disorders, Depts. of Neurology & Psychiatry, University of Cologne; and K. Fliessbach, Dept. of Neurology, University of Bonn.

Feature | PET Imaging | June 20, 2016
News | Prostate Cancer | June 17, 2016

June 17, 2016 — Decatur Memorial Hospital, Decatur, Ill., is now offering C-11 choline...

Michael J. Fox Foundation, MJFF, Parkinson's, PET tracer, competition, SNMMI 2016
News | PET Imaging | June 14, 2016

June 14, 2016 — The Michael J. Fox Foundation (MJFF) announced a $2 million prize for development of a...

PET-CT study, alcoholic brain, SNMMI 2016, mGluR5 receptor

Decreased mGluR5 availability in the brain of alcohol dependent individuals compared to healthy subjects. Image courtesy of Department of Nuclear Medicine and Molecular Imagine UZ Leuven, Leuven, Belgium

News | PET-CT | June 13, 2016

June 13, 2016 — An emerging molecular...

Loma Linda University, Siemens PETNET Solutions, PET facility, production and research
News | Nuclear Imaging | June 09, 2016

June 9, 2016 – Loma Linda University and Siemens’ PETNET Solutions Inc. have completed and brought operational a...

nuclear medicine, global market, radiopharmaceuticals, MEDraysintell, SNMMI 2016
News | Nuclear Imaging | June 08, 2016

June 8, 2016 — MEDraysintell estimates that the global market for...

NaF-PET/CT, sodium fluoride, advanced prostate cancer, metastases, pilot study
News | PET-CT | June 07, 2016

June 7, 2016 — A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium...

Axumin, fluciclovine F-18 injection, PET imaging agent, recurrent prostate cancer, Blue Earth Diagnostics, Siemens PETNET Solutions
Technology | Radiopharmaceuticals and Tracers | June 07, 2016

June 7, 2016 — Blue Earth Diagnostics Ltd. and Siemens’ PETNET Solutions Inc. announced the commercial availability...

PET, PET imaging, PET-CT, FDG PET, PET cancer assessment

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

Feature | PET Imaging | June 03, 2016 | Dave Fornell

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that...